GeoVax Announces 1-for-24 Reverse Stock Split to Regain Nasdaq Compliance

GeoVax Labs will implement a 1-for-24 reverse stock split on November 11, 2026, to raise its share price above the $1.00 minimum bid required for continued listing on the Nasdaq Capital Market.

Chicago Metrowire Staff
••Healthcare
GeoVax Announces 1-for-24 Reverse Stock Split to Regain Nasdaq Compliance

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, will effect a 1-for-24 reverse stock split of its common stock, the company announced. The move is aimed at regaining compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The split was approved by stockholders at a meeting on October 27, 2026, and will become effective at 12:01 a.m. ET on November 11, 2026.

Under the split, every 24 issued and outstanding shares will automatically convert into one share, reducing the total from 12,209,871 to approximately 508,745 shares. The par value remains unchanged at $0.001 per share. The stock will continue to trade under the symbol “GOVX” on a split-adjusted basis at the market open on the effective date, with a new CUSIP number, 373678 804. Each stockholder’s percentage ownership and proportional voting power will remain unchanged, except for minor adjustments from rounding fractional shares to the nearest whole number. The rights and privileges of stockholders will be substantially unaffected.

The reverse split is primarily a compliance measure. A sub-$1 share price puts GeoVax at risk of delisting from Nasdaq, which could reduce liquidity and limit access to capital markets. Regaining compliance helps preserve the company’s listing status and may improve its ability to raise funds as it advances its clinical programs. GeoVax’s lead program, GEO-MVA, is a Modified Vaccinia Ankara–based vaccine targeting mpox and smallpox, advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 trial in late 2026. In oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity, which has completed a Phase 1/2 trial in advanced head and neck cancer and is being advanced into combination strategies.

While the split does not change the company’s fundamentals, it is a necessary step to maintain its Nasdaq listing and support ongoing development efforts. Investors should note that the reduced share count may lead to greater price volatility, and the company’s forward-looking statements carry risks detailed in its SEC filings. For more information, visit www.geovax.com. The announcement was distributed via NEWMEDIAWIRE.

Blockchain Registration

QR Code for Blockchain Registration